_256_384.jpg)
News | December 08, 2021
IPM registers 6 % yoy revenue growth in Nov 2021.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
He has more than 285 publications with 7,600 citations, 80 students have already been awarded Ph. D. degree under his able guidance and 20 postdoctoral associates have worked in his group
Sputnik M is a new member of the Sputnik vaccines family
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
Fujifilm India will be providing healthcare Imaging devices and equipment’s to increase the standards of the veterinary care in India.
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
Subscribe To Our Newsletter & Stay Updated
